The CNS market at a global scale has been one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms remain favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs.
The CNS disorders market may be segmented into numerous subcategories, including Alzheimer's disease (AD), epilepsy, insomnia, major depressive disorder (MDD), Parkinson's disease (PD), migraine, schizophrenia, attention-deficit hyperactivity disorder (ADHD), bipolar disorder among others. Antipsychotics were the largest CNS drug class. Patent expirations of key brands Seroquel and Zyprexa and many other drugs through 2012-2017 is emerging as one of the major challenges to segmental growth through 2017. The CNS sector has struggled recently, as product classes that have dominated treatment areas have come under increasing pricing pressure from generics or have been plagued with safety concerns.
The top players in the CNS market at a global level at this time are Johnson & Johnson, Pfizer, GSK, Eli Lilly, etc. Several of the top-selling CNS drugs have lost their patent protection, enabling generics to flood the market and eroding the sales figures of pharma companies.
This report analyzes the Global CNS Market in its research offering Analyzing the Global CNS Market 2018. The report is a comprehensive analysis of the global CNS industry.
The report begins with an introduction to CNS disorders. We analyze the basic CNS disorders such as ADHD, Alzheimer's disease, epilepsy, insomnia, major depressive disorder (MDD), migraine, Parkinson's disease, and Schizophrenia.
Moving to the next section, we analyze the global CNS market through a market overview and an analysis of the market by CNS drug classes. We also analyze the industry through an industry segmentation and an analysis of the leading industry products. We look at the sales figures of the leading products in the industry.
With the rapid advances in technology, it is no wonder that there are now many novel emerging drug classes available for the treatment of CNS disorders. Some of these novel emerging drug classes for CNS disorder treatment are analyzed in our report.
Competition in the industry is analyzed in the report, following which we move on to the analysis of the major players in the global CNS industry. Players in the industry are analyzed through a corporate profile, an analysis of their major business segments, their major products and services offered, and an analysis of their presence in the CNS market. We also look at their CNS R&D pipeline, along with the company strategy for future growth in the CNS industry. A SWOT analysis of the players completes the analysis of the major industry contributors.
Future perspective of the global CNS market completes this in-depth profile of the global CNS market from this report.
Table of Contents
A. Executive Summary
Companies Mentioned
- AstraZeneca
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson
- Pfizer